Substituted quinoline CCR5 receptor antagonists

A method of treating an inflammatory or immunoregulatory disorder comprising the administration to a patient in need thereof an effective amount of at least one compound of formulae (Ia) or (1b)

• 172
• enantiomers, diastereomers, salts and solvates thereof
• wherein
• R1 and R1* are independnently hydrogen, a substituted or unsubstituted amino, alkyl, haloalkyl, hydroxy, alkoxy or —C(O)OR9a;
• R2, R2*, R3 and R3* are independently hydrogen, alkyl, halogenated alkyl, halogen, substituted or unsubstituted amino, nitro, cyano, or alkoxy;
• R4 and R4 are independently hydrogen or one or more alkyl groups;
• R5 is
• (1) hydrogen, or
• (2) R9, R9-aminocycloalkyl, R9-aminocycloalkenyl, (alkoxy)carbonyl, (aryloxy)carbonyl, —SO2—R9, —C(═O)—NR7R9, —C(═O)—NR7—SO2R9, —C(═O)—R6, —C(═O)—R9, —C(═NR10)—R9, —C(═S)—R9, —C(═NR10)—NHR9, —C(═)S—NHR9, or —C(═S)—NR7—SO2R9 any of which can be substituted or unsubstituted;
• R6 is a group of formula
• 173
• R7 and R7* are independently hydrogen, substituted or unsubstituted C1-6 alkyl, or substituted or unsubstituted aryl;
• R9 is arylalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, alkyl, heterocyclylalkyl, aryl or heterocyclyl any of which can be substituted or unsubstituted;
• R9a is
• (1) hydrogen, or
• (2) arylalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, alkyl, heterocyclylalkyl, aryl or heterocyclyl any of which can be substituted or unsubstituted;
• R10 is
• (1) hydrogen, or cyano;
• (2) alkyl, or alkoxy, either of which optionally can be substituted;
• n is 0, 1, 2 or 3;
• and
• n* is 1, 2 or 3.